![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
Synthesized and characterized a series of
rhenium(I) trycarbonyl-based complexes with increased lipophilicity. Two of
these novel compounds were discovered to possess remarkable anticancer,
anti-angiogenic and antimetastatic activity in
vivo (zebrafish-human CRC xenograft model), being effective at very low
doses (1-3 µM). At doses as high as 250 µM the complexes did not provoke
toxicity issues encountered in clinical anticancer drugs (cardio-, hepato-, and
myelotoxicity). The two compounds exceed the antiproliferative and
anti-angiogenic potency of clinical drugs cisplatin and sunitinib-malate, and
display a large therapeutic window.
